A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
A Phase 1b/2 Study of AV-299 (Formerly SCH 900105) in Combination With Gefitinib in Asian Subjects With Non-Small Cell Lung Cancer (P06162)
Sponsor: AVEO Pharmaceuticals, Inc.
A PHASE1/PHASE2 clinical study on Carcinoma, Non-Small Cell-Lung and Lung Cancer, this trial is completed. The trial is conducted by AVEO Pharmaceuticals, Inc. and has accumulated 7 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Dec 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AVEO Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .